2024年KSoLA关于新降脂剂的更新:英克利西兰和佩多酸
Hack-Lyoung Kim1, Jung-Joon Cha2, Sang-Hak Lee3
1Division of Cardiology, Department of Internal Medicine, Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
Journal of lipid and atherosclerosis
|June 10, 2025
概括
英克利西兰和贝佩多酸是新的非他类药物疗法,有效降低LDL胆固醇. 恩克利西兰可以将LDL-C降低50%,而贝佩多酸可以降低17-21%的LDL-C,肌肉副作用更少.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 英克利西兰和贝佩多酸是美国和欧洲批准的新兴非他类降脂剂.
- 这些药物为管理高脂血症提供了替代性或辅助性策略,特别是在他类药物不耐受或禁忌的患者中.
研究的目的:
- 审查inclisiran和bempedoic酸的作用机制,疗效,安全性和临床应用.
- 为了比较它们在初级和二级心血管预防中的作用.
主要方法:
- 英克利西兰:小干扰RNA向PCSK9mRNA,通过脂质纳米颗粒传递,用于肝脏吸收.
- 班佩多酸:口服的腺三酸酸酶 (ACL) 抑制剂,降低肝脏胆固醇合成.
主要成果:
- 在第三阶段试验中,Inclisiran显示LDL-C降低了50%,具有可接受的安全性;临床结果数据正在等待.
- 班佩多酸降低了17% - 21%的LDL-C,在对他类药物不耐受的患者中显示出临床益处,痛风和胆病发病率略有增加.
结论:
- 英克利西兰和贝佩多酸是降脂药物武器库中宝贵的补充,它们提供了不同的机制和有效性.
- 它们被推作为心血管预防的非一线药物,通常在服用他类药物之后或与其结合使用,考虑患者特异性因素和耐受性.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
581
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
581
Dipeptidyl Peptidase 4 Inhibitors
177
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
177
Atherosclerosis III: Management
2
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
2
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
155
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
155
Drugs for Treatment of Constipation-Predominant IBS
140
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
140
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
483
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
483


